Detection and diagnosis of Alzheimer's
.
Alzheimer's Donation
Donate Online Now
.
Alzheimer's Donation
Donate Online Now
.
A world leader in developing molecular imaging agents, Avid's technology can target amyloid plaque in the brain for detection and diagnosis of Alzheimer's disease (AD), which affects approximately 4.5 million Americans.
According to the Alzheimer's Association, it is estimated that a new case of AD occurs in the U.S. every 72 seconds, and by mid century the rate will greatly increase to one case every 33 seconds. The potential benefits of Avid's technology to the patient and overall public health are very promising, generating strong demand. Avid's first novel compound 18F-AV1/ZK (AV-1), devised for early diagnosis and disease progression monitoring of AD, has completed Phase I clinical trials and is to be used in conjunction with positron emission tomography (PET). Building on the positive clinical data with AV-1, Avid advanced a series of second generation PET molecular imaging compounds into clinical trials - these compounds provide further improvements in image quality for detecting amyloid plaque in the brains of people with AD. Avid is also testing related compounds in clinical trials for use with single photon emission computed tomography (SPECT).
"By accurately diagnosing AD in its earliest stages, Avid's products may enable more appropriate treatment plans to be devised for patients, thus reducing the long-term cost of care," says Frost & Sullivan Research Analyst Samantha Barbosa. "Bayer Schering Pharma has executed a licensing agreement for Avid's first agent, AV-1 to develop the compound, underscoring the potential clinical value of this technology in the marketplace. Now, Avid is developing a second generation PET molecular imaging compound in IND clinical trials for imaging amyloid plaques."
Researchers are also studying the utilization of this compound for monitoring the efficacy of drugs that may reverse or prevent the deposition of amyloid plaque in the brain. Avid's technology has the potential to yield the first commercially available molecular imaging agent with the capabilities to successfully image plaque in AD patients and others with mild cognitive impairment (MCI). "The possible value to the end users such as radiologists, neurologists, and nuclear medicine physicians is the concept of early detection of AD at a time when treatment may be more beneficial," notes Barbosa. "Moreover, with early detection comes early diagnosis and treatment that will enable appropriate life planning."
Response level in the scientific community is highly enthusiastic since the results from the reports released on the clinical trial showed a positive outcome. Through its innovative contribution to molecular imaging with amyloid imaging compounds for patients with AD, Avid is poised to make a major impact on the medical imaging industry, and stands to significantly improve management of Alzheimer's disease. Therefore, Frost & Sullivan is pleased to present Avid with the Technology Innovation of the Year award in molecular imaging. http://www.worldhealth.net
Carotenoid-rich tomatoes linked to cholesterol cuts
Including tomato products such a sauce and juice into the...
posted YVN
A world leader in developing molecular imaging agents, Avid's technology can target amyloid plaque in the brain for detection and diagnosis of Alzheimer's disease (AD), which affects approximately 4.5 million Americans.
According to the Alzheimer's Association, it is estimated that a new case of AD occurs in the U.S. every 72 seconds, and by mid century the rate will greatly increase to one case every 33 seconds. The potential benefits of Avid's technology to the patient and overall public health are very promising, generating strong demand. Avid's first novel compound 18F-AV1/ZK (AV-1), devised for early diagnosis and disease progression monitoring of AD, has completed Phase I clinical trials and is to be used in conjunction with positron emission tomography (PET). Building on the positive clinical data with AV-1, Avid advanced a series of second generation PET molecular imaging compounds into clinical trials - these compounds provide further improvements in image quality for detecting amyloid plaque in the brains of people with AD. Avid is also testing related compounds in clinical trials for use with single photon emission computed tomography (SPECT).
"By accurately diagnosing AD in its earliest stages, Avid's products may enable more appropriate treatment plans to be devised for patients, thus reducing the long-term cost of care," says Frost & Sullivan Research Analyst Samantha Barbosa. "Bayer Schering Pharma has executed a licensing agreement for Avid's first agent, AV-1 to develop the compound, underscoring the potential clinical value of this technology in the marketplace. Now, Avid is developing a second generation PET molecular imaging compound in IND clinical trials for imaging amyloid plaques."
Researchers are also studying the utilization of this compound for monitoring the efficacy of drugs that may reverse or prevent the deposition of amyloid plaque in the brain. Avid's technology has the potential to yield the first commercially available molecular imaging agent with the capabilities to successfully image plaque in AD patients and others with mild cognitive impairment (MCI). "The possible value to the end users such as radiologists, neurologists, and nuclear medicine physicians is the concept of early detection of AD at a time when treatment may be more beneficial," notes Barbosa. "Moreover, with early detection comes early diagnosis and treatment that will enable appropriate life planning."
Response level in the scientific community is highly enthusiastic since the results from the reports released on the clinical trial showed a positive outcome. Through its innovative contribution to molecular imaging with amyloid imaging compounds for patients with AD, Avid is poised to make a major impact on the medical imaging industry, and stands to significantly improve management of Alzheimer's disease. Therefore, Frost & Sullivan is pleased to present Avid with the Technology Innovation of the Year award in molecular imaging. http://www.worldhealth.net
Including tomato products such a sauce and juice into the...
posted YVN
posted by Valery Yermalitsky at
6:51 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home